• A persistent tension between disease framing and abstinence/harm-reduction aims shapes addiction research, with disease concepts of alcoholism and critiques of abstinence driving service design, while longitudinal outcomes highlight relapse as a central treatment endpoint [2], [4], [6], [10], [12], [14].

• Neuropharmacology and biological correlates highlight how morphine and other drugs alter brain catecholamines and serotonin, with studies on receptor-related changes and abstinence effects, alongside standardized inventories to quantify subjective drug effects [1], [3], [5], [13], [15], [16].

• A methodological thread emphasizes psychometric instruments and outcome measurement—MMPI factor analyses, Addiction Research Center Inventory, and long-term follow-ups—that operationalize addiction phenotypes and track treatment impact [9], [12], [13], [14], [19].

• Animal models of morphine addiction and tolerance, plus human experimental paradigms (escape training, self-regulated re-addiction) illustrate early conditioning-based frameworks for addiction pathways [3], [7], [8], [17], [18].

• Longitudinal investigations of mortality, relapse, abstinence, and post-treatment trajectories reveal the complex, protracted nature of recovery and the limits of initial interventions [4], [10], [12], [14], [19].